Table 1.
Baseline demographic and clinical characteristics of SLE patients treated with belimumab.
| N (%) or median (IQR)1 | |
|---|---|
| Gender (female) | 180 (95.7) |
| Age (years) | 48.4 (19.5) |
| Disease duration (years) | 6.2 (9.5) |
| Non smokers | 91 (48.4) 1 |
| Previous treatments (excluding glucocorticoids) | |
| Hydroxychloroquine | 148 (78.7) |
| Methotrexate | 137 (72.9) |
| Leflunomide | 34 (18.1) |
| Calcineurin inhibitors | 16 (8.5) |
| Azathioprine | 102 (54.3) |
| Mycophenolate | 26 (13.8) |
| Thalidomide | 4 (2.1) |
| Cyclophosphamide | 33 (17.6) |
| Rituximab | 20 (10.6) |
| IVIG | 7 (3.7) |
| Other biologics | 4 (2.1) |
| Disease state | |
| SLEDAI-2K | 8 (3) |
| SLEDAI-2K ≥10 | 43 (22.9) |
| Active serology 2 | 70 (37.2) |
| PGA | 1.5 (0.5) |
| Organ damage (SDI >0) | 74 (39.4) |
1 Interquartile range; 2 Data available on n=174 patients; 3 low C3/C4 and/or high anti-dsDNA titres.